drugset
Drugs / CD318-CAR-T cells
last change Jul 2026 re-read 3 minutes ago

CD318-CAR-T cells

Cell therapy

Developed for
pancreatic ductal adenocarcinoma
Investigated by
Berlin Institute of Health · Miltenyi Biotec B.V. & Co. KG · National Center for Tumor Diseases, Heidelberg · Technical University of Munich · University Hospital Freiburg · University Hospital Tuebingen
+1 more · Wuerzburg University Hospital

Trials 1

today NCT07153289 · Ph 1/2
202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07153289 Jul 2026 → Dec 2028 expected pancreatic ductal adenocarcinoma University Hospital Tuebingen Not yet recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CD318-CAR-T cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT07153289 ↗
Modality Cell therapy “autologous CD318-targeted chimeric antigen receptor (CAR) T-cell therapy” NCT07153289 ↗